Research Article

The Association between Type-2 Diabetes Duration and Major Adverse Cardiac Events after Percutaneous Coronary Intervention

Table 1

Demographic and baseline characteristics.

Diabetes duration for trend#
<5 years5 to 10 years>10 years

Number ()165 (54.6%)72 (23.8%)65 (21.5%)
Gender: male, %107 (55.7%)42 (21.9%)43 (22.4%)0.561
Gender: female, %58 (52.7%)30 (27.3)22 (20%)
Age0.141$
Life style modification %164 (99.4%)72 (100%)65 (100%)0.546
OHA %112 (67.9%)63 (87.5%)56 (86.2%)0.001
Insulin %35 (21.2%)27 (37.5%)33 (50.8%)0.001
OHA and insulin %28 (17%)22 (30.6%)27 (41.5%)0.001
Smoking %55 (33.3%)19 (26.4%)20 (30.8%)0.568
Hypertension %111 (67.3%)50 (69.4%)43 (66.2%)0.913
Heart failure %103 (62.4%)50 (69.4%)46 (70.8%)0.372
Prior MI %24 (14.5%)14 (19.4%)13 (20%)0.489
Prior stroke %21 (12.7%)14 (19.4%)11 (16.9%)0.380
EF %0.141$
BNP Pg/ml0.006$
CK-MB, U/L0.351$
cTnT, ng/L0.982$
HGB, g/L0.178$
Glucose, mmol/L0.707$
HbA1C, %0.069$
Urea, mmol/L0.075$
Creatinine, mmol/L0.203$
eGFR, mL/min/1.73m20.088$
T. Cholesterol, mg/dL0.444$
HDL, mmol/L0.763$
LDL, mmol/L0.656$
Triglyceride, mmol/L0.153$
Albumin, g/L0.152$
Medication
 Aspirin + clopidogrel110 (67%)36 (50%)35 (54%)0.034
 Aspirin + ticagrelor55 (33.3%)36 (50%)30 (46.1%)
 ACE inhibitor29 (18%)17 (24%)13 (20%)0.497
 Beta blockers123 (75%)48 (67%)44 (68%)0.321
 Statin165 (100%)72 (100%)65 (100%)0.000

Data are reported as or (%). OHA: oral hypoglycemic agent; MI: myocardial infarction; EF: ejection fraction; BNP: brain natriuretic peptide; CK-MB: creatinine kinase myocardial band; cTnT: cardiac troponin T; HGB: hemoglobin; HbA1C: glycosylated hemoglobin; eGFR: estimated glomerular filtration rate; T. cholesterol: total cholesterol; HDL: high-density lipoprotein; LDL: low-density lipoprotein; ACE: angiotensin-converting enzyme. #Statistical significances for categorical variables were tested using X2 test for trend. $Statistical significances were tested by one-way ANOVA with trend analysis for continuous variables.